What are the latest figures on the metronidazole market’s size and projected CAGR?
The metronidazole market size has grown strongly in recent years. It will grow from $0.58 billion in 2024 to $0.62 billion in 2025 at a compound annual growth rate (CAGR) of 6.2%. The growth in the historic period can be attributed to favorable healthcare reimbursement policies, increasing funding for infectious disease research, a growing incidence of oral and dental infections, a rising prevalence of inflammatory bowel diseases, and a growing elderly population.
The metronidazole market size is expected to see strong growth in the next few years. It will grow to $0.78 billion in 2029 at a compound annual growth rate (CAGR) of 5.9%. The growth in the forecast period can be attributed to the increasing prevalence of bacterial and protozoal infections, rising cases of gastrointestinal disorders, growing demand for affordable generic antibiotics, expanding healthcare infrastructure, and government initiatives to combat infectious diseases. Major trends in the forecast period include advancements in pharmaceutical manufacturing, strategic collaborations between pharmaceutical companies, expansion of pharmaceutical contract manufacturing organizations, adoption of nanotechnology-based drug delivery systems, and advancements in pH-responsive metronidazole formulations.
Get Your Free Sample of The Global Metronidazole Market Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=21222&type=smp
Which Market drivers have played a significant role in driving the metronidazole market?
The increasing incidence of bacterial infections is expected to propel the growth of the metronidazole market going forward. Bacterial infections are diseases caused by the growth and multiplication of harmful bacteria in the body. The increasing incidence of bacterial infections is driven by factors such as antibiotic resistance, environmental changes, and the rise in immunocompromised populations. Metronidazole targets bacterial DNA, causing damage that halts reproduction and spread. This makes it effective against anaerobic bacteria and certain protozoal infections, inhibiting bacterial growth and treating the infection. For instance, in November 2023, according to the UK Health Security Agency (UKHSA), a UK-based government agency, in 2022, an estimated 58,224 individuals in England were affected by antibiotic-resistant infections, marking a 4% increase from 2021, when the figure was 55,792. The number of deaths resulting from severe antibiotic-resistant infections also rose, from 2,110 in 2021 to 2,202 in 2022. Therefore, the increasing incidence of bacterial infections will drive the growth of the metronidazole market.
What are the key segments within the metronidazole market?
The metronidazole market covered in this report is segmented –
1) By Formulation Type: Tablets, Capsules, Intravenous (IV) Solutions, Topical Creams Or Ointments, Other Formulation Types
2) By Application: Bacterial Infections, Parasitic Infections, Gynecological Infections, Surgical Prophylaxis, Other Applications
3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Other Distribution Channels
4) By End-User: Hospitals, Clinics, Homecare, Other End Users
Subsegments:
1) By Tablets: Immediate Release Tablets, Extended Release Tablets
2) By Capsules: Immediate Release Capsules, Extended Release Capsules
3) By Intravenous (IV) Solutions: Single-dose IV Solutions, Multi-dose IV Solutions
4) By Topical Creams Or Ointments: Topical Creams, Topical Ointments
5) By Other Formulation Types: Oral Suspension, Vaginal Gels Or Suppositories
Order your report now for swift delivery
https://www.thebusinessresearchcompany.com/report/metronidazole-global-market-report
Which key players are shaping the metronidazole market?
Major companies operating in the metronidazole market are Pfizer Inc., Merck & Co. Inc., Abbott Laboratories, Fresenius Kabi AG, Baxter International Inc., Sandoz Group AG, Sun Pharmaceutical Industries Ltd., Aurobindo Pharma Limited, Cipla Limited, Dr. Reddy’s Laboratories Ltd., Lupin Pharmaceuticals Inc., Zydus Lifesciences, YiChang HEC ChangJiang Pharmaceutical Co. Ltd., Aarti Drugs Ltd., Unichem Laboratories, Cosette Pharmaceuticals Inc., Saptalis Pharmaceuticals LLC, Huanggang Saikang Pharmaceutical Co. Ltd., Kesin Pharma, Hubei Hongyuan Pharmaceutical Technology Co. Ltd., Huanggang Yinhe Aarti Pharmaceutical Co. Ltd., Higgs Healthcare
Which transformative trends will shape the metronidazole market landscape?
Major companies operating in the metronidazole market are focusing on developing advanced products, such as ready-to-use oral liquids, to enhance patient compliance, especially for those who have difficulty swallowing tablets or require easier administration for the treatment of infections. Ready-to-use oral liquids are pre-formulated liquid medications that do not require further preparation or mixing before administration, providing convenience for patients. For instance, in November 2023, Kesin Pharma Corporation, a US-based specialty pharmaceutical company, announced that the Food and Drug Administration (FDA) approved LIKMEZ (metronidazole) oral suspension, 500 mg/5 mL. It is a novel formulation of a common antibiotic drug designed to improve patient adherence and approved for treating trichomoniasis and anaerobic bacterial infections in adults, as well as amebiasis in adults and children. LIKMEZ is presented as a strawberry peppermint-flavored suspension in a 200 mL bottle, with a 24-month shelf life that does not require refrigeration.
How do regional factors impact the metronidazole market, and which region is the largest contributor?
Asia-Pacific was the largest region in the metronidazole market in 2024. The regions covered in the metronidazole market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
What Does The Metronidazole Market Report 2025 Offer?
The metronidazole market research report from The Business Research Company offers global market size, growth rate, regional shares, competitor analysis, detailed segments, trends, and opportunities.
Metronidazole is an antibiotic and antiprotozoal drug used to treat bacterial and parasitic infections. It works by penetrating microbial cells, where bacterial and protozoal enzymes reduce it, generating reactive nitrogen species. These reactive compounds damage DNA, causing strand breakage and inhibiting nucleic acid synthesis, ultimately disrupting replication and transcription, leading to cell death.
Purchase the exclusive report now to unlock valuable market insights:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21222
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.
Our flagship product, the Global Market Model, is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
